Semax and Selank: Sequence, Origin, and Evidence-Source Matching
Semax and Selank are different synthetic peptides, despite often appearing together under the broad term “nootropic.” Semax is an ACTH-fragment analogue, while Selank is a tuftsin-related analogue. A shared research label does not establish a shared sequence, mechanism, or outcome, and findings about one should not be presented as evidence for the other.
Begin with the molecule, not the category
Semax is the heptapeptide Met–Glu–His–Phe–Pro–Gly–Pro. The primary Semax literature identifies it as an analogue of ACTH(4–10). Selank follows a different design history: its literature describes a synthetic analogue based on the endogenous peptide tuftsin. These descriptions identify distinct starting points for research, rather than two interchangeable names. Dolotov et al., 2006; Kolik et al., 2019
In practical terms, Semax belongs with Semax-specific references and Selank with Selank-specific references. A search result mentioning both may be a useful introduction, but it is not a substitute for checking which material the experiment actually used.
“Nootropic” is a broad functional or commercial label, not a molecular definition. It does not specify a receptor, a measurement, or the quality of the evidence. The Research Compounds collection is useful for finding separate materials; scientific interpretation still begins with their exact names.
Why BDNF appears in both research discussions
BDNF means brain-derived neurotrophic factor. In the papers discussed here it is a measured biological endpoint, not a universal score of cognitive performance. The key question is not simply whether BDNF changed, but where, relative to which comparator, and in what model.
The 2006 Semax study examined the rat hippocampus and measured BDNF-related gene expression, BDNF protein, and TrkB-related outcomes, alongside a behavioral task. The results connected several levels of measurement within that particular experiment. They did not by themselves identify one exclusive molecular mechanism for every reported Semax effect. Semax hippocampal study
By contrast, the 2019 Selank experiment used an ethanol-exposure model in rats and assessed object recognition together with BDNF content in brain regions. An intervention in that altered biological state answers a different question from an experiment without the same exposure history. Selank rat study
Compare the experiments before comparing the peptides
| Question | Semax example | Selank example |
|---|---|---|
| Which material? | ACTH-fragment analogue Semax | Tuftsin analogue Selank |
| Which model? | Rat hippocampal investigation | Rats with a defined ethanol-exposure history and comparison animals |
| Which measurements? | BDNF and TrkB-related molecular measurements; conditioned avoidance | BDNF content in specified brain regions; object recognition |
| What does the paper contribute? | Evidence connecting Semax exposure with measured responses in that model | Evidence about Selank responses in a different experimental context |
| What remains unanswered? | Whether the same response occurs in other settings or materials | Whether findings generalize beyond the study conditions |
The table describes two primary studies, not the total evidence for either peptide. It also illustrates why counting positive-sounding findings is a poor comparison method. Two papers can mention the same biological factor while studying different questions.
A changed marker does not settle the mechanism
A measurement can sit at several levels. Messenger RNA is evidence about transcription. Protein content is another measurement. Receptor phosphorylation provides information about a signaling state. Behavioral performance is a still broader endpoint influenced by the animal and the testing environment.
Those measurements may agree, but agreement does not automatically establish that one caused all the others. A strong causal explanation needs experiments that distinguish competing mechanisms. This is particularly relevant when a summary compresses multiple endpoints into a phrase such as “works through BDNF.” That phrase may imply more certainty than the study design supports.
Our discussion of Semax gene-expression evidence examines a related issue: a list of changed genes can generate hypotheses, but it cannot independently establish a functional benefit. The same care applies when interpreting an isolated protein measurement.
What a useful Semax-versus-Selank question looks like
“Which is better?” leaves the endpoint undefined. More useful questions include whether the studies used comparable species, whether their baseline conditions differed, and whether the measurement was behavioral or molecular. These questions reveal what could reasonably be compared before any conclusion is drawn.
An informative direct comparison would place both clearly identified materials into an appropriately controlled design and examine the same predefined outcome. The selected studies above do not do that. Their value is in describing separate experimental observations, not in producing a cross-product ranking.
Naming also matters during searches. A modified derivative should not automatically inherit the evidence of the parent name. For a broader explanation of how abbreviations and derivatives affect source selection, see peptide names and synonyms.
Limits of the evidence and the material record
The studies summarized here use animal models, and this article is not a systematic review of clinical evidence. It does not establish effectiveness in people, clinical suitability, or equivalence between commercial materials and the research preparations.
There is a separate analytical question whenever a supplied material is considered: what does its documentation establish? The relevant COA should be read for its identified sample and methods. The peptide COA guide explains why identity and purity are distinct findings. Scientific papers describe their own experiments; they do not verify a lot from the NEXTWAVE PEPTIDES catalog.
FAQ
Are Semax and Selank interchangeable?
No. Their peptide identities and research histories differ. A shared category or discussion of BDNF does not establish interchangeability.
Does an increase in BDNF always mean an improvement?
A direction of change needs biological context. The tissue, starting condition, comparator, and functional measurements determine what can be inferred; the marker alone is not a general outcome score.
Does “ACTH analogue” mean Semax is full-length ACTH?
No. The cited study defines a particular seven-residue analogue. A relationship to an ACTH fragment does not make it the full hormone.
Can these studies rank Semax against Selank?
No. They used different experimental settings and were not a matched comparison of the two peptides. Ranking them would require evidence designed for that purpose.
Why keep molecular and behavioral findings separate?
They answer different questions. Recording both preserves the study's detail without assuming that one marker explains an entire behavioral response.